Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole Maintenance in PPI-Resistant GERD
NCT02135107Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rabeprazole in gastroesophageal reflux disease (GERD), sponsored by Eisai Co., Ltd.. Started Sep 2013; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02135107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135107.